Ocugen, Inc/$OCGN
1D1W1MYTD1Y5YMAX
Capital at risk
About Ocugen, Inc
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
- Ticker
- $OCGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 116
- Headquarters
- Malvern, United States
- Website
- www.ocugen.com
Ocugen, Inc Metrics
BasicAdvanced
$348M
-
-$0.26
-
-
Price and volume
Market cap
$348M
52-week high
$2.73
52-week low
$1.01
Average daily volume
5.5M
Financial strength
Current ratio
0.802
Quick ratio
0.752
Long term debt to equity
-28.799
Total debt to equity
-531.445
Interest coverage (TTM)
-8.16%
Profitability
EBITDA (TTM)
-67.173
Gross margin (TTM)
-855.32%
Net profit margin (TTM)
-1,785.88%
Operating margin (TTM)
-1,504.08%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-48.44%
Return on equity (TTM)
1,211.66%
Valuation
Price to revenue (TTM)
71.764
Price to book
-20.99
Price to tangible book (TTM)
-20.99
Price to free cash flow (TTM)
-5.387
Free cash flow yield (TTM)
-18.56%
Free cash flow per share (TTM)
-0.19
Growth
Revenue change (TTM)
-3.64%
Earnings per share change (TTM)
29.08%
3-year revenue growth (CAGR)
10.28%
3-year earnings per share growth (CAGR)
-13.81%
What the Analysts think about Ocugen, Inc
Analyst ratings (Buy, Hold, Sell) for Ocugen, Inc stock.
Analyst projections of the future price of Ocugen, Inc stock.
Bulls say / Bears say
OCU410 has entered a global Phase 3 trial for geographic atrophy, and the FDA granted RMAT designation, which can provide enhanced agency interaction and eligibility for accelerated approval and priority review. (Ocugen)
OCU400’s Phase 3 liMeliGhT trial has completed enrollment, and Ocugen reported completed process-performance qualification batches, supporting its planned BLA and potential commercial manufacturing strategy. (Ocugen)
The May 2026 convertible financing generated approximately $112.5 million in net proceeds after expenses and debt repayment, with management projecting cash runway into 2028; a separate OCU400 MENA licensing term sheet offers up to $4 million in upfront and near-term milestones plus 22% royalties on net sales. (Ocugen Ocugen)
Ocugen’s Q2 2026 10-Q states that substantial doubt remains about its ability to continue as a going concern, despite $100.1 million of cash at June 30, 2026, because of recurring losses, expected negative operating cash flow, and future clinical spending. (SEC)
The company remains loss-making and cash-burning: six-month 2026 net loss was approximately $44.1 million, while operating expenses rose to $37.3 million from $31.2 million a year earlier. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Ocugen, Inc Financial Performance
Revenues and expenses
Ocugen, Inc Earnings Performance
Company profitability
Upcoming events
No upcoming events
Ocugen, Inc News
AllArticlesVideos
Funds containing Ocugen, Inc
Fund name | Fund size | $OCGN weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.